TITLE

FAULDING TO MARKET ENALAPRILAT INJECTION/ENALAPRIL TABLETS

PUB. DATE
October 2000
SOURCE
Worldwide Biotech;Oct2000, Vol. 12 Issue 10, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces that F H Faulding & Co. Limited's Faulding Pharmaceuticals division has received final approval from the United States Food and Drug Administration for its abbreviated new drug application (ANDA) for enalaprilat injection.
ACCESSION #
3635169

 

Related Articles

  • Stock of the week. Way, Nicholas // BRW;09/30/96, Vol. 18 Issue 38, p76 

    Focuses on the stock of pharmaceutical manufacturer and distributor F.H. Faulding. Drop in Faulding's profit; Three divisions of the company; Possible benefit of the company from an ageing population and the move toward pharmaceutical treatment from surgery.

  • Bloomberg.  // Business News New Jersey;3/6/96, Vol. 9 Issue 5, p46 

    Reports that stockholders approved the acquisition of three companies owned by Purepac's largest shareholder F.H. Faulding and a change in Purepac's name.

  • Faulding in Indonesian deal.  // Asian Business Review;Mar1995, p17 

    Reports that Australian pharmaceutical company FH Faulding has signed a cooperation and technological assistance agreement with Indonesia's PT Tempo Group.

  • Extra herbs. Watson, Paul // BRW;10/14/96, Vol. 18 Issue 40, p12 

    Tells that Australia's largest pharmaceutical company, F.H. Faulding, is moving into herbal products. Recognition of the continuing community shift to natural therapies; Faulding's acquisition of the Sydney-based vitamin company Cenovis, the leading supplier of vitamins to supermarkets.

  • Company man goes it alone. Kennedy, Alex; Way, Nicholas // BRW;1/30/95, Vol. 17 Issue 3, p34 

    Features Australian executive Chris Harris. Decision to resign as chief executive officer of F.H. Faulding & Co. Ltd.; Career background; Character and personality; Education.

  • Faulding on the block. Quinlivan, Beth // BRW;05/11/2001, Vol. 23 Issue 18, p34 

    Focuses on developments related to Australia-based pharmaceutical company F.H. Faulding as of May 11, 2001. Company background; Financial performance; Company's search for a merger partner.

  • Faulding sees a remedy in growth.  // BRW;07/28/97, Vol. 19 Issue 28, p22 

    Reports that the pharmaceutical group F.H. Faulding & Co. is set to announce a $120-million rights issue to finance a buyout of its United States operation and build the most sophisticated retail pharmacy network in Australia. Chief executive officer Ed Tweddell's five year strategy; Details of...

  • Alpharma Nears Completion of Faulding Business.  // Chemical Market Reporter;10/08/2001, Vol. 260 Issue 13, p12 

    Reports what generics pharmaceutical producer Alpharma Inc. expects from its purchase of F.H. Faulding & Co. Limited's generic oral solid dose pharmaceutical. Businesses that Alpharma will acquire; Estimated revenues from the acquired businesses in 2000; View of analysts on the deal.

  • Mayne's Bid for Faulding Portends Purepac Sale.  // Chemical Market Reporter;6/11/2001, Vol. 259 Issue 24, p8 

    Reports on the possible sale of Purepac Pharmaceutical Co. following a bid by Mayne Nickless Ltd. to acquire F.H. Faulding & Co. Ltd., Purepac's parent company. Value of the acquisition deal; Potential bidders for Purepac; Analysis of the synergies between Faulding and Mayne.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics